Allelica announced that it is working with Invitae to build and refine an ancestry-informed polygenic risk score (PRS) for breast cancer. Invitae is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare.

The companies will combine Allelica's innovative approach for leveraging multiple datasets to improve the prediction of PRS across different genetic ancestries with Invitae's clinical reach, physician network, and development capabilities of innovative genomics products.

A PRS for breast cancer can inform when women should begin breast cancer screening and which screening modality they should use in order to detect the disease as early as possible. Polygenic factors and pathogenic variants in moderate- and high-risk genes account for similar proportions of the familial relative risk of breast cancer. Allelica's collaboration with Invitae involves the development and validation of a new PRS for breast cancer and its integration with absolute risk models to estimate 10-year and lifetime risk in women of multiple ancestries.

Together, Allelica and Invitae aim to decrease the gap in PRS performance in individuals from diverse genetic ancestries, ensuring that the lifesaving integration of genomic information into breast cancer risk assessments can benefit all women.

PR teams collaborate to drive valuable media coverage

Working in close collaboration with Invitae’s PR team, ZingPR was able to secure media coverage across a range of key publications.